Long‐term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder

Abstract

Approximately one-quarter of previously untreated Japanese overactive bladder female patients continue solifenacin treatment for 3 years. Many patients discontinue solifenacin for various reasons, including symptom resolution and adverse events.

Persistence and adherence to overactive bladder medications in Japan: A large nationwide real‐world analysis

“…13,14 Previous studies, each from a single healthcare site, have investigated persistence with OAB medications in the Japanese patient population, and recent investigations have shown that 12-month persistence rates with mirabegron vary between 12% and 29%. [15][16][17][18] Building on these results, the present study is the first large-scale, nationwide survey in Japan to explore persistence and adherence to mirabegron and antimuscarinics using data from two databases.…”

Safety, efficacy, and persistence of long‐term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1‐year) report from a Japanese post‐marketing surveillance study

“…Historically, oral antimuscarinic agents have been the mainstay of OAB therapy, although the associated side‐effects (including dry mouth and constipation) further affect quality of life and adversely affect treatment adherence . Treatment persistence of OAB medication is lower than for any other chronic disease therapy, with a number of studies demonstrating poor treatment persistence with antimuscarinics . As such, OAB treatments with alternative mechanisms of action and improved tolerability are desirable.…”

“…4,5 Treatment persistence of OAB medication is lower than for any other chronic disease therapy, 6 with a number of studies demonstrating poor treatment persistence with antimuscarinics. [7][8][9][10][11][12][13][14][15][16][17][18] As such, OAB treatments with alternative mechanisms of action and improved tolerability are desirable.…”

How long do we have to treat overactive bladder syndrome? A questionnaire survey of Canadian urologists and gynecologists

“…The resolution of bothering symptoms has been given as one of the most common reasons for termination of treatment and may be achieved in more than one-third of OAB cases. [11][12][13][14][15] Other common reasons for medication discontinuation are adverse effects and/or failure of expected clinical outcome. There is no consensus regarding the optimal duration of OAB treatment as, in the vast majority of available clinical trials, time periods of drug administration have been reported to range from 2 weeks to 12 months.…”

“…A prospective study from Japan (n=73), assessing persistence rates of solifenacin 5 mg daily treatment during a 3-year period, demonstrated that 25% of patients required retreatment at an average 10 months after termination. 12 Until now, there is paucity of data on the impact of physiotherapy on OAB recurrence after treatment cessation. Further research in this area is warranted as behavioral therapies, including pelvic floor muscle exercises, are relatively non-invasive and could benefit patient health overall.…”